GTS-21, also known as DMBX-A, is a derivative of the natural product anabaseine that acts as a partial agonist at neural nicotinic acetylcholine receptors. It binds to both the 42 and 7 subtypes, but activates only the 7 to any significant extent. Both GTS-21 itself and its demethylated active metabolite 4-OH-GTS-21 display nootropic[4] and neuroprotective effects, and GTS-21 is being investigated for the treatment of Alzheimer's disease, nicotine dependence,[10] and, most significantly, for schizophrenia. (https://en.wikipedia.org/wiki/GTS-21).
For research use only. We do not sell to patients.